Thelansis

Essential thrombocytosis (ET), or essential thrombocythemia, is categorized as a myeloproliferative neoplasm (MPN). It is characterized by a persistent elevation in platelet count in the blood (above 450 x 10^9/L) and a propensity for abnormal clotting and bleeding. The predominant genetic mutations associated with ET are somatic in the JAK2 gene. Additionally, mutations in the LNK gene can induce ET by suppressing the JAK2 pathway, and mutations in the MPL gene are implicated in cases of ET accompanied by myeloproliferation. Symptoms of ET can vary, ranging from an absence of symptoms to microcirculatory disturbances or vasomotor events, including headaches, visual disturbances, atypical chest pain, distal paresthesias, and erythromelalgia. The primary risks for ET patients are arterial and venous thromboses, which have the potential to result in severe neurological, cardiac, or peripheral artery complications. Initially, the overall survival rate of ET patients mirrors that of a heal...